NASDAQ · AQST
Healthcare · Drug Manufacturers - Specialty & Generic
$5.38
Down-$0.03 (-0.56%)
Updated Sep 4, 2026, 1:18 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AQST closed at $5.38 after 20 trading sessions, up 37.24% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $5.25 | $5.39 | $5.25 | $5.38 | 1.81M |
| Sep 1, 2026 | $5.15 | $5.35 | $5.09 | $5.24 | 2.17M |
| Aug 31, 2026 | $4.975 | $5.125 | $4.91 | $5.11 | 1.91M |
| Aug 28, 2026 | $5.11 | $5.18 | $4.9736 | $5.02 | 2.52M |
| Aug 27, 2026 | $5.39 | $5.395 | $5.115 | $5.16 | 3.66M |
| Aug 26, 2026 | $5.08 | $5.409 | $5.01 | $5.39 | 3.41M |
| Aug 25, 2026 | $4.77 | $5.12 | $4.72 | $5.08 | 3.67M |
| Aug 24, 2026 | $4.67 | $4.82 | $4.56 | $4.80 | 2.61M |
| Aug 21, 2026 | $4.54 | $4.72 | $4.52 | $4.66 | 2.02M |
| Aug 20, 2026 | $4.61 | $4.64 | $4.39 | $4.495 | 2.67M |
| Aug 19, 2026 | $4.31 | $4.745 | $4.31 | $4.59 | 8.42M |
| Aug 18, 2026 | $4.27 | $4.39 | $4.25 | $4.32 | 5.46M |
| Aug 17, 2026 | $4.22 | $4.35 | $4.20 | $4.29 | 3.34M |
| Aug 14, 2026 | $4.20 | $4.28 | $4.015 | $4.25 | 4.35M |
| Aug 13, 2026 | $4.25 | $4.39 | $4.14 | $4.25 | 3.75M |
| Aug 12, 2026 | $4.27 | $4.44 | $4.19 | $4.23 | 9.12M |
| Aug 11, 2026 | $4.30 | $4.69 | $4.24 | $4.41 | 6.5M |
| Aug 10, 2026 | $4.35 | $4.635 | $4.26 | $4.29 | 7.3M |
| Aug 7, 2026 | $3.95 | $4.035 | $3.865 | $3.94 | 1.86M |
| Aug 6, 2026 | $3.76 | $3.92 | $3.76 | $3.92 | 1.54M |
The latest Smart Investors Daily articles mentioning AQST.
AQST research
Company profile and research snapshot.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | Piper Sandler | Overweight | — |
| Oct 9, 2025 | JMP Securities | Market Outperform | — |
| Sep 8, 2025 | Oppenheimer | Outperform | — |
| Jun 17, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 24, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:AQST) with a Buy and maintains $10 price target.
SeekingAlpha · Aug 19, 2026
Aquestive Therapeutics (AQST) is highlighted for its growth potential, driven by upcoming NDA resubmission for Anaphylm, an orally delivered epinephrine...
Yahoo · Aug 18, 2026
Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears.
Yahoo · Aug 12, 2026
Company advances toward Q3 NDA resubmission with improved human factors data, while total revenue climbs to $13.8 million and adjusted EBITDA loss narrows to $5.2 million.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AQST.
